In the BioHarmony Drug Report Database
Etoposide
Vepesid (etoposide) is a small molecule pharmaceutical. Etoposide was first approved as Vepesid on 1983-11-10. It is used to treat brain neoplasms, ewing sarcoma, histiocytosis, kaposi sarcoma, and lung neoplasms amongst others in the USA. The pharmaceutical is active against DNA topoisomerase 2-alpha. In addition, it is known to target DNA topoisomerase 2-beta.
Trade Name
|
Vepesid |
|---|---|
Common Name
|
etoposide |
ChEMBL ID
|
CHEMBL44657 |
Indication
|
brain neoplasms, ewing sarcoma, histiocytosis, kaposi sarcoma, lung neoplasms, mycosis fungoides, myeloid leukemia acute, neuroblastoma, prostatic neoplasms, rhabdomyosarcoma, testicular neoplasms, trophoblastic neoplasms, urinary bladder neoplasms, uterine neoplasms |
Drug Class
|
Image (chem structure or protein)